NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $13.97 +0.14 (+1.01%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ClearPoint Neuro Stock (NASDAQ:CLPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ClearPoint Neuro alerts:Sign Up Key Stats Today's Range$13.71▼$14.1350-Day Range$12.88▼$16.9652-Week Range$8.27▼$30.10Volume373,356 shsAverage Volume555,228 shsMarket Capitalization$426.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.67Consensus RatingHold Company Overview ClearPoint Neuro, Inc. develops and commercializes image-guided systems designed to support minimally invasive procedures involving the brain. Its technology is intended to help physicians plan, navigate and monitor neurosurgical interventions while using magnetic resonance imaging (MRI) guidance. The company’s principal product is the ClearPoint Neuro Navigation System, which combines specialized software, MRI-compatible instruments and accessories to assist with procedures such as deep brain stimulation, laser ablation and the delivery of therapeutic agents to targeted areas of the brain. ClearPoint Neuro also provides related products and services for clinical research, pharmaceutical development and advanced biologic delivery. The company was previously known as MRI Interventions, Inc. and adopted the ClearPoint Neuro name in 2020. Based in Solana Beach, California, ClearPoint Neuro serves hospitals, physicians, research institutions and life-sciences partners in the United States and selected international markets. Joe Burnett serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More ClearPoint Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCLPT MarketRank™: ClearPoint Neuro scored higher than 42% of companies evaluated by MarketBeat, and ranked 605th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingClearPoint Neuro has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialClearPoint Neuro has a consensus price target of $25.67, representing about 83.7% upside from its current price of $13.97.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($1.22) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -11.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -11.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 14.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.77% of the float of ClearPoint Neuro has been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 8.55.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 6.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ClearPoint Neuro this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $387,600.00 in company stock.Percentage Held by Insiders6.94% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by Institutions30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLPT Stock News HeadlinesClearPoint Neuro (NASDAQ:CLPT) and IceCure Medical (NASDAQ:ICCM) Financial SurveySeptember 21 at 8:29 AM | americanbankingnews.comClearPoint Neuro (CLPT) Q2 2026 Earnings Call TranscriptAugust 10, 2026 | finance.yahoo.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment CaseAugust 4, 2026 | seekingalpha.comClearPoint Neuro, Inc. (CLPT) Q2 2026 EarningsAugust 4, 2026 | 247wallst.comClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call TranscriptAugust 4, 2026 | seekingalpha.comClearPoint Neuro (CLPT) Stock Falls on Q2 2026 EarningsAugust 3, 2026 | quiverquant.comQWhy I've (Reluctantly) Sold My ClearPoint Neuro PositionJuly 13, 2026 | seekingalpha.comSee More Headlines CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $13.68 on January 1st, 2026. Since then, CLPT stock has increased by 2.1% and is now trading at $13.97. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its quarterly earnings results on Monday, August, 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.09. The company earned $10.88 million during the quarter, compared to the consensus estimate of $12.73 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 188.09% and a negative net margin of 81.76%. Read the conference call transcript. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's top institutional investors include BlackRock Inc. (7.80%), Compass Financial Management LLC (0.97%), Compass Financial Management LLC (0.97%) and Bank of New York Mellon Corp (0.50%). Insiders that own company stock include Joseph Burnett, Timothy T Richards, Lynnette C Fallon and Matthew B Klein. View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ClearPoint Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO). Company Calendar Last Earnings8/03/2026Today9/21/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CLPT's financial health is in the Green zone, according to TradeSmith. CLPT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CLPT CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees172Year Founded1998Price Target and Rating Average Price Target for ClearPoint Neuro$25.67 High Price Target$30.00 Low Price Target$22.00 Potential Upside/Downside+83.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.54 million Net Margins-81.76% Pretax Margin-81.80% Return on Equity-188.09% Return on Assets-40.88% Debt Debt-to-Equity Ratio4.66 Current Ratio4.74 Quick Ratio3.89 Sales & Book Value Annual Sales$36.97 million Price / Sales11.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.99 per share Price / Book14.11Miscellaneous Outstanding Shares30,500,000Free Float28,387,000Market Cap$426.09 million OptionableOptionable Beta1.26 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CLPT) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
